SAB Biotherapeutics SABS Stock
$3.46
1.466270%
Add to favorites
SECTOR
INDUSTRY
COUNTRY
Exchange
Market Cap
$314.81M
LOW - HIGH [24H]
$3.40
-
$3.51
VOLUME [24H]
$237.47K
P/E Ratio
14.41
Earnings per share
$0.24
ISIN
US78397T2024
SAB Biotherapeutics Price Chart
SAB Biotherapeutics SABS Financial and Trading Overview
| SAB Biotherapeutics stock price | 3.46 USD |
| Previous Close | 3.41 USD |
| Open | 3.42 USD |
| Bid | 2.48 USD x 200 |
| Ask | 4.35 USD x 200 |
| Day's Range | 3.4 - 3.51 USD |
| 52 Week Range | 1.85 - 5.15 USD |
| Volume | 70.89K USD |
| Avg. Volume | 666.87K USD |
| Market Cap | 318M USD |
| Beta (5Y Monthly) | 0.538 |
| PE Ratio (TTM) | 14.5625 |
| EPS (TTM) | 0.24 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.64 USD |
SABS Valuation Measures
| Enterprise Value | 212.76M USD |
| Trailing P/E | 14.5625 |
| Forward P/E | -3.6627538 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.3588647 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -3.097 |
Trading Information
SAB Biotherapeutics Stock Price History
| Beta (5Y Monthly) | 0.538 |
| 52-Week Change | 62.38% |
| S&P500 52-Week Change | 15.74% |
| 52 Week High | 5.15 USD |
| 52 Week Low | 1.85 USD |
| 50-Day Moving Average | 3.7 USD |
| 200-Day Moving Average | 3.81 USD |
SABS Share Statistics
| Avg. Volume (3 month) | 666.87K USD |
| Avg. Daily Volume (10-Days) | 259.15K USD |
| Shares Outstanding | 90.99M |
| Float | 62.04M |
| Short Ratio | 10.95 |
| % Held by Insiders | 0.70% |
| % Held by Institutions | 75.42% |
| Shares Short | 4.12M |
| Short % of Float | 4.67% |
| Short % of Shares Outstanding | 4.53% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -33.45% |
| Return on Equity (ttm) | -11.26% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -48268332 USD |
| EBITDA | -68707776 USD |
| Net Income Avi to Common (ttm) | -21787718 USD |
| Diluted EPS (ttm) | 0.24 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 102.63M USD |
| Total Cash Per Share (mrq) | 1.13 USD |
| Total Debt (mrq) | 5.13M USD |
| Total Debt/Equity (mrq) | 2.39 USD |
| Current Ratio (mrq) | 9.221 |
| Book Value Per Share (mrq) | 2.572 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -53937112 USD |
| Levered Free Cash Flow (ttm) | -28842384 USD |
Profile of SAB Biotherapeutics
| Country | United States |
| State | FL |
| City | Miami Beach |
| Address | 777 W 41st St. |
| ZIP | 33140 |
| Phone | 305 845 2813 |
| Website | https://www.sab.bio |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 86 |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Q&A For SAB Biotherapeutics Stock
What is a current SABS stock price?
SAB Biotherapeutics SABS stock price today per share is 3.46 USD.
How to purchase SAB Biotherapeutics stock?
You can buy SABS shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for SAB Biotherapeutics?
The stock symbol or ticker of SAB Biotherapeutics is SABS.
Which industry does the SAB Biotherapeutics company belong to?
The SAB Biotherapeutics industry is Biotechnology.
How many shares does SAB Biotherapeutics have in circulation?
The max supply of SAB Biotherapeutics shares is 90.99M.
What is SAB Biotherapeutics Price to Earnings Ratio (PE Ratio)?
SAB Biotherapeutics PE Ratio is 14.41666700 now.
What was SAB Biotherapeutics earnings per share over the trailing 12 months (TTM)?
SAB Biotherapeutics EPS is 0.24 USD over the trailing 12 months.
Which sector does the SAB Biotherapeutics company belong to?
The SAB Biotherapeutics sector is Healthcare.
SAB Biotherapeutics SABS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26186.41 USD — |
-0.56
|
6.24B USD — | 25992.55 USD — | 26329.98 USD — | — - | 6.24B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2212.82 USD — |
-0.16
|
— — | 2197.04 USD — | 2231.45 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6989.76 USD — |
+0.94
|
— — | 6923.95 USD — | 7012.55 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1308.52 USD — |
+1.15
|
— — | 1296.22 USD — | 1310.89 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}
